Wockhardt Q2 FY27 PAT at ₹73 Cr, Revenue Jumps 24% to ₹969 Cr
Wockhardt reported Q2 FY27 PAT of ₹73 crore, up from a loss in H1 FY26. Revenue grew 24% YoY to ₹969 crore in Q2 FY27 and 25% YoY to ₹1,898 crore in H1 FY27. Biotech operations surged 68% in Q2 and 87% in H1. Emerging markets revenue increased 52% in Q2. Zaynich received US FDA approval.
The announcement includes substantial revenue growth, key product approvals (like Zaynich from US FDA), successful completion of clinical trials for novel antibiotics, and strong performance in high-growth segments like Biotech and Emerging Markets, which are material to the company's future prospects.
The company reported significant revenue growth in both quarterly and half-yearly periods, alongside strong performance in its biotech segment and emerging markets. Key product approvals and successful clinical trial completions also contribute to a positive outlook.
Wockhardt Limited announced its un-audited financial results for the quarter and half-year ended September 30, 2026. The company reported a Profit After Tax (PAT) of ₹73 crore for the second quarter of FY27, a decrease from ₹82 crore in the same quarter last year. However, total revenue for Q2 FY27 saw a significant increase of 24%, reaching ₹969 crore compared to ₹782 crore in Q2 FY26. EBITDA for the quarter stood at ₹165 crore, slightly up from ₹160 crore in the previous year, and ₹201 crore excluding pre-Zaynich launch expenses.
For the first half of FY27, Wockhardt reported a PAT of ₹180 crore, a substantial turnaround from a loss of ₹26 crore in H1 FY26. Revenue for H1 FY27 grew by 25% to ₹1,898 crore from ₹1,520 crore in the prior year. EBITDA for H1 FY27 increased by 35% to ₹353 crore compared to ₹261 crore in H1 FY26, and ₹398 crore excluding pre-Zaynich launch expenses.
The Biotech operations showed robust growth, with Q2 FY27 revenue at ₹252 crore (up 68% YoY) and H1 FY27 revenue at ₹487 crore (up 87% YoY), driven by emerging markets and strategic partnerships.
Region-wise, India Branded Business grew 8% in Q2 FY27 to ₹146 crore and 14% in H1 FY27 to ₹303 crore. Emerging Markets saw a strong growth of 52% in Q2 FY27 to ₹310 crore and 54% in H1 FY27 to ₹574 crore, primarily fueled by the Biotech Insulin segment.
In terms of new product launches and approvals, Wockhardt reported 24 filings, 18 approvals, and 11 launches in its International Business. Notably, five novel antibiotics, including Emrok®, Emrok O®, Miqnaf®, Zaynich®, and Foviscu®, have completed Phase 3 clinical trials successfully. Zaynich® received US FDA approval on May 29, 2026, for cUTI, and is undergoing EMA review. EMROK®/EMROK O® showed a growth rate of 40% vs Q2 FY26. Miqnaf® has been approved and launched in India, with plans for additional indication filings. FOVISCU® (WCK 4282) has completed Phase 2 & 3 trials in India, and its NDA filing is complete.
The company also filed 7 patents and was granted 6 patents during Q2 FY27.
What to do with a filing like this
Wockhardt Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Wockhardt Limited. Read the original for the full detail.